Supplemental Material for:Implementation gaps after CGP across cancer types

<p dir="ltr"><b>Introduction </b>Comprehensive genomic profiling (CGP) has been reimbursed in Japan since 2019; however, the extent to which treatments recommended by expert panels are subsequently implemented and how this varies across cancer types remain unclear.</p><p dir="ltr"><b>Methods</b> Among 50,974 patients with solid tumors registered in the C-CAT database between June 2019 and April 2023, 44,669 adult patients met the eligibility criteria and were included in the analysis.

Patients were grouped into three cohorts: non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and other solid tumors. We evaluated the proportion of patients with at least one drug-based treatment recommended by an expert panel (PoTR) and the proportion who subsequently received an expert-panel–recommended treatment (PoTI). We also conducted exploratory multivariable analyses of factors associated with PoTR and, among patients who received a treatment recommendation, PoTI.</p><p dir="ltr"><b>Results</b> The PoTR was 54.57% for NSCLC, 53.80% for CRC, and 39.92% for other solid tumors.